Progyny just finished digesting the loss of a single employer that had been a double-digit slice of sales. The remaining book is growing again in the low double digits once that transition revenue is stripped out of the year-ago quarter. Care-management efficiencies and a sharp drop in stock compensation are lifting reported profit much faster than sales. The market still treats the name as a broken compounder rather than a cleaned-up one.
The operating tension sits underneath the headline. Assisted reproductive treatment cycles barely moved even as membership and client count rose, which means growth is coming from more employers rather than heavier use per covered life. Pharmacy revenue is almost flat because the company absorbed certain cost increases to keep clients whole. That mix is why reported growth looks mid-single digit while fertility services carry the print. Share repurchases since last autumn have retired a large slug of the share count and are doing as much work for per-share earnings as the operating line.
Management says early selling-season commits are pacing ahead of last year and that most large-account retention risk is already off the table. Third-quarter guidance embeds a deeper summer pause in member activity. The investment question is whether the next selling season refills a million new lives and restores a cleaner double-digit run rate, or whether utilization per member has structurally cooled.